Document:

Exhibit

	
			
	 
	Union Carbide Corporation and Subsidiaries
	EXHIBIT 10.7.8

	 
	 
	 

Eighth Amendment to Second Amended and Restated Revolving Loan Agreement

This Eighth Amendment to the Second Amended and Restated Revolving Loan Agreement (the “Amendment”), effective as of April 26, 2017, is entered into by and between Union Carbide Corporation, a New York corporation (the “Lender”) and The Dow Chemical Company, a Delaware corporation (the “Borrower”).

WHEREAS, the Lender and the Borrower are parties to the Second Amended and Restated Revolving Loan Agreement dated as of November 1, 2005, amended by the First Amendment effective December 31, 2007, amended by the Second Amendment effective August 1, 2009, amended by the Third Amendment effective February 1, 2010, amended by the Fourth Amendment effective August 1, 2010, amended by the Fifth Amendment effective August 1, 2011, amended by the Sixth Amendment effective April 1, 2012, and amended by the Seventh Amendment effective August 1, 2013 (the “Loan Agreement”);

WHEREAS, the Lender and the Borrower wish to extend the Maturity Date, as defined in the Loan Agreement and as contemplated herein:

NOW, THEREFORE, in view of the following terms and conditions and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.    Section 1.12 definition of “Maturity Date” in the Loan Agreement is deleted in its entirety and replaced with the following Section 1.12 definition of “Maturity Date”:

“Maturity Date” means April 30, 2022.

2.    No Other Amendment or Waiver.  Except as expressly amended by this Amendment, the Loan Agreement remains in full force and effect in accordance with its terms.

3.    Execution in Counterparts.  This Amendment may be executed in any number of counterparts, each of which when so executed will be deemed to be an original and all of which taken together will constitute one and the same agreement.  Signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are attached to the same document.

4.    Governing Law.  This Amendment and the rights and obligations of the parties to this Amendment will be governed by and construed and interpreted in accordance with the laws of the State of New York.

5.    Ratification.  Lender and Borrower agree that this Amendment is effective as of April 26, 2017, and each party ratifies all action taken up to and in accordance with this Amendment.

62

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their authorized representatives.

	
			
	THE DOW CHEMICAL COMPANY
	 
	UNION CARBIDE CORPORATION

	 
	 
	 

	 
	 
	 

	 
	 
	 

	By:  /s/ ANDREAS UNTERSTE
	 
	By:  /s/ IGNACIO MOLINA

	Name:  Andreas Unterste
	 
	Name:  Ignacio Molina

	Title:    Director of Financial Operations And Planning
	 
	Title:    Chief Financial Officer, Vice President, and Treasurer

Signature Page
Eighth Amendment to the Second Amended and Restated Revolving Loan Agreement

63Exhibit 10.1

 

SETTLEMENT
AGREEMENT

 

This
settlement agreement (the “Agreement”) is entered into as of the date on which the parties deliver executed original
counterparts of this Agreement to each other (“Effective Date”), by and between Roche Diagnostics GmbH, a German corporation
having its principal place of business at Sandhofer Str. 116, 68305, Mannheim, Germany and Roche Molecular Systems, Inc., a Delaware
corporation having its principal place of business at 4300 Hacienda Dr., Pleasanton, 94588 California (together, “Roche”)
and Enzo Biochem, Inc., having its principal place of business at 527 Madison Avenue, New York, New York, and Enzo Life Sciences,
Inc. (formerly known as Enzo Diagnostics, Inc.), having its principal place of business at 527 Madison Avenue, New York, New York
(together “Enzo”). Each of the foregoing entities is sometimes referred to as a “Party” and they are sometimes
referred to together as the “Parties.”

 

WHEREAS, Roche
brought an action against Enzo in the United States District Court, Southern District of New York, captioned Roche Diagnostics
GmbH et al. v. Enzo Biochem, Inc. et al., Case No. 04-CV-4046-DLC, and Enzo asserted counterclaims against Roche in
that action (the “NY Action”);

 

WHEREAS,
Enzo and Roche mutually desire to resolve the differences between them regarding the NY Action subject to the terms and conditions
of this Agreement.

 

For
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1 “Affiliate”
means, as of the Effective Date,: (a) an organization, which directly or indirectly controls such entity; (b) an organization,
which is directly or indirectly controlled by such entity; or (c) an organization, which is controlled, directly or indirectly,
by the ultimate parent company of such entity. Control as per (a) to (c) is defined as owning more than fifty percent (50%) of
the voting stock of a company or having otherwise the power to govern the financial and the operating policies or to appoint the
management of an organization.

 

1.2 “Diagnostic
Product” means reagents, kits, instruments, consumables, software, systems, accessories and replacement parts that are intended
for use or eventual use in the diagnosis or screening of disease or other conditions, including a determination of the state of
health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection,
preparation, and examination of specimens. The definition of Diagnostic Product also includes services performed through use of
such products. For the avoidance of doubt, the definition of Diagnostic Product includes at least all products marketed or sold
by Roche and/or its Affiliates under the Cobas, Taqman, Amplicor, AmpliChip, and Elecsys tradenames, including “research
use only” and “investigational use only” versions of such products.

    	 

    	

    

ARTICLE
II

SETTLEMENT
AMOUNT

 

2.1 No
later than five (5) business days after the Effective Date, Roche shall pay twenty-one million USD ($21,000,000.00) to Enzo Biochem,
Inc. (the “Settlement Payment”) as follows:

 

	 	a.	$1,575,000 to Greenberg Traurig, LLP, by wire transfer to:
	 	 	 	 
	 	 	Bank:	 
	 	 	 	 
	 	 	Routing No.:	 
	 	 	 	 
	 	 	Name on Acct.:	 
	 	 	 	 
	 	 	Account Number:	 
	 	 	 	 
	 	 	Reference:	Enzo v. Roche,
	 	 	 	 
	 	 	and	 
	 	 	 	 
	 	b.	$19,425,000 to Enzo Biochem, Inc. by wire transfer to
	 	 	 	 
	 	 	Bank:	 
	 	 	 	 
	 	 	Routing No.	 
	 	 	 	 
	 	 	Name on Acct:	 
	 	 	 	 
	 	 	Account No.	 

 

Enzo
represents and warrants to Roche that: (i) it is obligated to disburse a portion of the Settlement Payment to Greenberg Traurig
as specified above; (ii) there is no basis for any third party other than Greenberg Traurig to assert any lien or claim with respect
to the Settlement Payment; and (iii) no third party other than Greenberg Traurig has asserted any claim to any of the Settlement
Payment. Enzo agrees to indemnify and hold Roche harmless and further agrees to pay Roche’s fees and costs in connection
with any claims made by Greenberg Traurig for proceeds from the Settlement Payment.

 

Enzo shall
acknowledge receipt of payment within no more than five (5) business days by email to robert.gunther@wilmerhale.com. The
Parties acknowledge and agree that this Agreement is enforceable according to its terms with respect to Roche’s payment obligation
under this Article II. In the event that Roche fails to pay Enzo the Settlement Payment no later than five (5) business days after
Effective Date, Enzo shall have the right to commence a lawsuit

 

-2-

    	 

    	

    

to compel
Roche to pay the Settlement Payment, and Roche shall pay Enzo’s costs, including reasonable attorneys’ fees, of that
lawsuit.

 

ARTICLE
III

RELEASES
AND DISMISSAL OF NY ACTION

 

3.1 Roche Release of Enzo. Roche,
on behalf of itself and its Affiliates and all of their respective predecessors, successors and assigns (the “Roche Releasing
Parties”), releases, acquits, and forever discharges Enzo and its Affiliates and all of their respective predecessors, successors,
assigns, officers, directors, managers, members, employees, agents, insurers, servants, experts, consultants, customers, distributors
and attorneys (the “Enzo Released Parties”) from all liabilities, actions, causes of action, claims or demands, losses,
damages, attorneys’ fees, court costs, or any other form of claim or compensation from the beginning of the world to the
Effective Date arising from (a) any claims asscrted by Roche in the NY Action, including patent infringement claims relating to
any product identified in Exhibit E and claims for breach of the Distribution Agreement (defined below), (b) any patent infringement
claims that could have been asserted by Roche in the NY Action concerning the patents identified in Exhibit A and any claims for
breach of the Distribution Agreement (defined below) that could have been asserted by Roche in the NY Action, and (c) any claims
of infringement of Roche’s patents relating to Diagnostic Products of Enzo or its Affiliates, including for Enzo or its Affiliates’
customers’ use of or resale of such Diagnostic Products, on or before the Effective Date, provided that this release extends
only to Enzo’s or its Affiliates’ Diagnostic Products or their customers’ use of such Diagnostic Products in
the form they are sold by Enzo or its Affiliates. If any such customer combines any such Diagnostic Product with another product
that itself infringes Roche’s patents, or that in combination with any such Diagnostic Product creates a new product that
infringes Roche’s patents, then this release does not apply except where the infringement is due solely to the presence of
such Diagnostic Product. If any such customer separates or repackages any such Diagnostic Product, and such separation or repackaging
is not reasonably necessary for the use of such product or is not otherwise recommended by Enzo or its Affiliates for the use of
such product, then this release does not apply. For the avoidance of doubt, any conduct or activity of Enzo Released Parties or
customers of Enzo or its Affiliates that is not performed on behalf of or as intended by Enzo or its Affiliates is expressly excluded
from the release of this Section 3.1. Notwithstanding anything to the contrary in this Agreement, Section 3.1 does not release,
affect or otherwise limit the rights of Roche or Enzo with respect to (i) the litigation in the United States District Court, District
of Delaware, captioned Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et al., Civil Action No. 12-cv-00106,
any inter partes reviews of a patent-at-issue in that litigation (“IPRs”), and/or any appeal(s) from the litigation
or IPR(s) (together, the “Delaware Litigation”); (ii) any claims of infringement of one or both of U.S. Patent No.
6,992,180 and U.S. Patent No. 7,064,197 (together, the “Enzo Delaware Patents”), including but not limited to any claims
of infringement of the Enzo Delaware Patents relating to Diagnostic Products; or (iii) any claims of infringement of any patent
that is not listed in Exhibit A based on the manufacture, use, import, offering for sale or sale of products that are not Diagnostic
Products. This release applies only to the Roche Releasing Parties and the Enzo Released Parties as they exist on the Effective
Date. It does not apply to any entity or predecessor, successor, assign, officer, director, manager, member, employee, agent, insurer,
servant, expert, consultant or attorney of that entity that any

 

-3-

    	 

    	

    

Party
subsequently acquires, is acquired by, merges with, or enters into any other agreement or arrangement with.

 

Enzo Release
of Roche. Enzo, on behalf of itself and its Affiliates and all of their respective predecessors,
successors and assigns (the “Enzo Releasing Parties”), releases, acquits, and forever discharges Roche and its Affiliates
and all of their respective predecessors, successors, assigns, officers, directors, managers, members, employees, agents, insurers,
servants, experts, consultants, customers, distributors and attorneys (the “Roche Released Parties”) from all liabilities,
actions, causes of action, claims or demands, losses, damages, attorneys’ fees, court costs, or any other form of claim or
compensation from the beginning of the world to the Effective Date arising from (a) any claims asserted by Enzo in the NY Action,
including patent infringement claims relating to any product identified in Exhibit E and claims for breach of the Distribution
Agreement (defined below), (b) any patent infringement claims that could have been asserted by Enzo in the NY Action concerning
the patents identified in Exhibit A and any claims for breach of the Distribution Agreement (defined below) that could have been
asserted by Enzo in the NY Action, and (c) any claims of infringement of Enzo’s patents relating to Diagnostic Products of
Roche or its Affiliates, including for Roche or its Affiliates’ customers’ use of or resale of such Diagnostic Products,
on or before the Effective Date, provided that this release extends only to Roche’s or its Affiliates’ Diagnostic Products
or their customers’ use of such Diagnostic Products in the form they are sold by Roche or its Affiliates. If any such customer
combines any such Diagnostic Product with another product that itself infringes Enzo’s patents, or that in combination with
any such Diagnostic Product creates a new product that infringes Enzo’s patents, then this release does not apply except
where the infringement is due solely to the presence of such Diagnostic Product. If any such customer separates or repackages any
such Diagnostic Product, and such separation or repackaging is not reasonably necessary for the use of such product or is not otherwise
recommended by Roche or its Affiliates for the use of such product, then this release does not apply. For the avoidance of doubt,
any conduct or activity of Roche Released Parties or customers of Roche or its Affiliates that is not performed on behalf of or
as intended by Roche or its Affiliates is expressly excluded from the release of this Section 3.2. Notwithstanding anything to
the contrary in this Agreement, Section 3.2 does not release, affect or otherwise limit the rights of Roche or Enzo with respect
to (i) the Delaware Litigation; (ii) any claims of infringement of one or both of the Enzo Delaware Patents, including but not
limited to any claims of infringement of the Enzo Delaware Patents relating to Diagnostic Products; or (iii) any claims of infringement
of any patent that is not listed in Exhibit A based on the manufacture, use, import, offering for sale or sale of products that
are not Diagnostic Products. Section 3.2 also does not release, affect, or limit any claims of infringement of any patent asserted
by Enzo in the litigations listed in Exhibit C.

 

3.2 This
limited release is not a license to any patents or other intellectual property rights of Enzo, and does not convey any right to
any Enzo patents or to any products that constitute or incorporate any Diagnostic Products. This release applies only to the Enzo
Releasing Parties and the Roche Released Parties. It does not apply to any entity or predecessor, successor, assign, officer, director,
manager, member, employee, agent, insurer, servant, expert, consultant or attorney of that entity that any Party subsequently acquires,
is acquired by, merges with, or enters into any other agreement or arrangement with.

 

-4-

    	 

    	

    

3.3
Releases. The
releases specifically provided in this Agreement include an express, informed, knowing, and voluntary waiver and relinquishment
to the fullest extent permitted by law. In this connection, the Parties acknowledge that they may have sustained damages, losses,
costs, or expenses that are presently unknown and unsuspected and that such damages, losses, costs, or expenses as may have been
sustained may give rise to additional damages, losses, costs, or expenses in the future. The Parties acknowledge, and waive any
rights under, California Civil Code Section 1542, which provides as follows:

 

“A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME
OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

 

or any
similar or comparable law of any state, territory or jurisdiction, foreign or domestic, including the United States and federal,
state, county or local jurisdiction which is similar, comparable, or equivalent to Section 1542 of the California Civil Code.

 

3.4
Termination of the Distribution Agreement. The
Enzo Releasing Parties and the Roche Releasing Parties hereby acknowledge that the Distribution and Supply Agreement (the “Distribution
Agreement”), dated April 25, 1994, by and among Enzo Biochem, Inc. and Enzo Diagnostics, Inc. (now known as Enzo Life Sciences,
Inc.) and Corange International Limited (acquired by Roche in March 1998), is terminated. For the avoidance of doubt, the Enzo
Releasing Parties and the Roche Releasing Parties hereby release all obligations for any performance, and any and all claims for
breach, with respect to the Distribution Agreement.

 

3.5
Agreement Obligations Not Released. Notwithstanding
anything to the contrary herein, the Parties reserve all rights and remedies, including damages and equitable relief, for breach
of this Agreement and nothing herein releases any Party from its respective obligations under this Agreement or prevents any Party
from enforcing the terms and conditions of this Agreement against any other Party.

 

3.6
Joint Stipulation of Dismissal with Prejudice. Upon
Enzo’s acknowledgment of the receipt of payment described in Section 2.1, the Parties will file a Joint Stipulation of Dismissal
with Prejudice in the Southern District of New York in the form set forth in Exhibit B attached hereto. The Parties shall promptly
proceed with any and all additional procedures needed to dismiss with prejudice the NY Action including any modifications to the
forms to comply with any local rules or procedures regarding the entry of stipulated dismissals. The Parties acknowledge and agree
that this Agreement is enforceable according to its terms with respect to final dismissal with prejudice of the NY Action.

 

3.7
Mutual Standstill/Agreement Not to Sue. For
a period of two years following the Effective Date (the “Standstill Period”), the Enzo Releasing Parties agree that
they will not bring, assert or maintain, directly or indirectly, any claim, demand, liability and cause of action, in law or in
equity, for the infringement of any patent against Roche, its Affiliates, or their customers for such customer’s use of or
resale of Roche’s or its Affiliates’ products or Roche’s or its Affiliates’ services. For the Standstill
Period, the Roche Releasing Parties agree that they

 

-5-

    	 

    	

    

will not
bring, assert or maintain, directly or indirectly, any claim, demand, liability and cause of action, in law or in equity, for the
infringement of any patent against Enzo, its Affiliates, or their customers for such customer’s use of or resale of Enzo’s
or its Affiliates’ products or Enzo’s or its Affiliates’ services. This standstill does not affect or otherwise
limit any Party’s right to litigate or appeal any pending action (other than the NY Action), including but not limited to
those listed in Exhibit C attached hereto (and to the extent not listed in Exhibit C, also including the Delaware Litigation),
or any other pending litigation or future litigation involving one or both of the Enzo Delaware Patents. This Standstill Period
applies only to the Enzo Releasing Parties and the Roche Releasing Parties as they exist on the Effective Date, and not to any
claim, demand, liability or cause of action by or against any entity that any Party subsequently acquires, is acquired by, merges
with, or enters into any other agreement or arrangement with.

 

3.8 No
Effect On Other Actions. This Agreement, including the releases and standstill herein, do
not affect any other pending action by Enzo, including but not limited to those listed in Exhibit C attached hereto (and to the
extent not listed in Exhibit C, also including the Delaware Litigation), or any other pending litigation or future litigation involving
one or both of the Enzo Delaware Patents. This Agreement shall not be admissible in any other pending action by Enzo, including
but not limited to the actions listed in Exhibit C attached hereto, the Delaware Litigation, or any other pending litigation or
litigation filed in the future involving one or both of the Enzo Delaware Patents.

 

ARTICLE
IV

REPRESENTATIONS, WARRANTIES, AND DISCLAIMERS

 

4.1
Mutual Representations and Warranties. Each
Party represents and warrants to the other that: (a) each person executing this Agreement on its behalf has full authority to enter
into this Agreement; (b) it enters into this Agreement of its own free will and accord, upon advice of its own legal counsel; (c)
it has the authority to enter into and to perform or to cause performance of its obligations under this Agreement; (d) the execution
and delivery of this Agreement and the actions contemplated hereby have been duly authorized by all necessary corporate action
on the part of such Party; (e) this Agreement constitutes a valid and binding obligation of such Party, enforceable against it
in accordance with its terms; (f) no further approval is needed to make this Agreement valid, binding, and enforceable against
such Party; and (g) the execution and delivery of this Agreement will not violate, conflict with, or result in a breach of the
terms of any agreement by which such Party is bound or of any applicable statute, regulation, rule, or other law. Enzo further
specifically represents and warrants that, as of the Effective Date, Enzo has all requisite power and authority, corporate or otherwise,
to release and discharge claims under Section 3.2 arising from U.S. Patent Nos. 4,711,955, 5,328,824 5,449,767, and 5,476,928 (which
the parties acknowledge was invalidated) which patents are assigned to Yale University.

 

4.2
Roche Representation. Roche
represents that it has no present knowledge of, or intent to bring, any claim against Enzo, its Affiliates or any of their customers
(for such customer’s use of or resale of Enzo’s or its Affiliates’ products or Enzo’s or its Affiliates’
services) for infringement of any patents, patent applications or other intellectual property.

 

-6-

    	 

    	

    

4.3
Enzo Representation.
Enzo represents that it has no present knowledge of, or intent to bring, any claim against Roche, its Affiliates or any of their
customers (for such customer’s use of or resale of Roche’s or its Affiliates’ products or Roche’s or its
Affiliates’ services) for infringement of any patents, patent applications or other intellectual property, except for claims
relating to the Enzo Delaware Patents.

 

4.4
No Admission.
This Agreement is made in connection with a full, final, and complete satisfaction and compromise of disputed claims and matters.
Neither this Agreement nor any action taken in connection with this Agreement or pursuant to it constitutes an admission by any
Party or by any other person that any conduct or action was unlawful or in violation of any contract, agreement, understanding,
custom, or obligation among or between the Parties, or constituted any wrongdoing whatsoever. Other than the representations and
warranties made herein, each of the Parties acknowledges that if the facts with respect to which this Agreement is executed are
found hereafter to be different from what they now believe those facts to be, each expressly accepts and assumes the risk of such
possible differences and agrees that this Agreement shall be, and shall remain, effective, notwithstanding such differences.

 

ARTICLE
V

CONFIDENTIALITY

 

5.1
Confidentiality.
The Parties agree that the terms of this Agreement will remain confidential and will not be disclosed except to Greenberg Traurig,
LLP, and its counsel, or as required by law (for example, each Party may disclose information as required under securities laws
or other regulations in the jurisdictions where they are organized or do business or by further example inform customs or border
control or tax authorities in any jurisdiction), by rule, regulation or legal process (including by any stock exchange, the NASDAQ
National Market or the rules and regulations of the United States Securities Exchange Commission (the “SEC”) or any
applicable state securities regulators), by court order, or pursuant to a discovery request made pursuant to a protective order
entered by a court of competent jurisdiction, and in any case only to the extent required by such law, rule, regulation, legal
process, court order or discovery request. Without the express written consent of the other Party, the Parties shall not make any
public statements about the Agreement other than the statements set forth in Exhibit D.

 

ARTICLE
VI

MISCELLANEOUS

 

6.1
Notices.
All required communications under this Agreement shall be in writing, sent to the Party at its address below, or as otherwise designated
by the Party in accordance with this provision, and duly given or made: (a) on the date delivered in person; (b) on the date transmitted
by electronic mail, if confirmation is received from the recipient; (c) three days after deposit in the mail if sent by certified
U.S. mail postage prepaid, return receipt requested; or (d) one day after deposit with a nationally recognized overnight carrier
service with charges prepaid.

 

	If to Roche:	Marc Bächli
	 	Head Legal Centralised and Point of Care Solutions
	 	General Counsel, Roche Diagnostics International
	 	Roche Diagnostics International Ltd

 

-7-

    	 

    	

    

	 	Forrenstrasse 2

6343 Rotkreuz, Switzerland
	 	 
	 	Kevin A. Marks

VP, General Counsel

Head of Legal and Compliance

Roche Molecular Solutions, Inc.

4300 Hacienda Drive

Pleasanton, California 94588
	 	 
	with a copy to:	Robert J. Gunther, Jr.

Wilmer Cutler Pickering Hale and Dorr LLP

7 World Trade Center

250 Greenwich Street

New York, New York 10007
	 	 
	If to Enzo:	Enzo Biochem

    527 Madison Avenue

    New York, New York 10022

    Attention: Barry Weiner

    bweiner@enzo.com
	 	 
	with a copy to:	Michael J. Dell

Kramer Levin Naftalis & Frankel LLP

1177 Avenue of the Americas

New York, NY 10036

 

6.2 Governing
Law/Entire Agreement. This Agreement shall be governed by the laws of the state of New York
without regard to any conflict-of-laws provisions. This Agreement, including its exhibits, constitutes the entire agreement between
the Parties with respect to the subject matter hereof, and supersedes all other previous and contemporaneous agreements, understandings,
negotiations, discussions, offers, and acceptances with respect to such subject matter. This Agreement may not be modified except
in writing signed by authorized representatives of the Parties. The delay or failure to assert a right or to insist upon compliance
with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure
to perform any such term or condition. A valid waiver must be executed in writing and signed by the Party granting the waiver.
Each Party acknowledges that it was provided an opportunity to seek advice of counsel and as such this Agreement shall not be strictly
construed against the drafter. Subject to Section 6.5 below, this Agreement shall be binding on and inure to the benefit of each
of the Parties and their successors and permitted assigns.

 

6.3
Severability. The
provisions of this Agreement are severable, and if any provision of this Agreement is determined to be invalid or unenforceable
under any controlling body of law, such invalidity or non-enforceability shall not in any way affect the validity or enforceability
of the remaining provisions or the validity or enforceability of such provision in

 

-8-

    	 

    	

    

any
jurisdiction where valid and enforceable. Any invalid or unenforceable provision will be reformed by the Parties to effectuate
their intent as evidenced on the Effective Date. The Parties may execute this Agreement in one or more counterparts, each of which
shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

 

6.4 No
Costs and Fees. Subject to the last sentence of
Section 2.1 of this Agreement, each Party shall bear its own costs, expenses, and attorneys’ fees and shall take all such
additional steps and actions reasonably requested by any other Party as may be necessary or desired to effect the dismissal of
the NY Action.

 

6.5 Assignment:
This Agreement may be assigned by Roche without
the consent of Enzo, or by Enzo without the consent of Roche, each in connection with the sale of all or substantially all of its
assets, any merger, reorganization or consolidation, or a sale of all or substantially all of its business relating to any Diagnostic
Products, or any merger, consolidation, reorganization, stock exchange, sale of stock, or other similar or related transaction
in which it is the sole, surviving entity to conduct the business it conducted prior to the consummation of the transaction. Other
than as set forth in the foregoing, neither Party may assign this Agreement (in whole or in part) without the prior written consent
of the other Party and any such assignment will be deemed void ab initio.

 

6.6 Miscellaneous:

 

a. Failure
by any Party to detect, protest, or remedy any breach of this Agreement shall not constitute a waiver or impairment of any such
term or condition, or the right of such Party at any time or condition. A waiver may only occur pursuant to the express written
permission of an authorized officer of the Party against whom the waiver is asserted.

 

b. This
Agreement is the result of negotiations between the Parties and accordingly shall not be construed for or against any one Party
merely because such Party drafted this Agreement or any portion thereof.

 

c. This
Agreement may be executed in counterparts, each of which will be deemed an original and all of which together constitute one instrument.
Executed counterparts of this Agreement sent and received via facsimile or electronic transmission means shall be deemed originals
for all purposes.

 

d. In
the event any term, condition or provision of this Agreement is declared or found by a court of competent jurisdiction to be illegal,
unenforceable or void, the Parties shall endeavor in good faith to agree to amendments that will preserve, as far as possible,
the intentions expressed in this Agreement. If the Parties fail to agree on such amendments, such invalid term, condition or provision
shall be severed from the remaining terms, conditions and provisions, which shall continue to be valid and enforceable to the full
extent permitted by law.

 

e.
Nothing in this Agreement grants to any Party by implication, estoppel, or otherwise any rights to any other Party’s intellectual
property beyond those explicitly set forth herein.

 

-9-

    	 

    	

    

f.
Except as expressly provided herein, this Agreement is not intended to confer any benefits or rights upon any Person not a Party
to this Agreement.

 

	ROCHE DIAGNOSTICS GMBH	 	ENZO BIOCHEM, INC.
	 	 	 	 	 	 
	By:	/s/ Dr. Joachim Eberle	/s/ Dr. Kai Simon	 	By:	          
	 	 	 	 	 	 
	[Name] 	Dr. Joachim Eberle	 Dr. Kai Simon	 	[Name] 	 
	[Title]	Head of Research and Development	Head Legal Penzberg	 	[Title]	 
	 	 	 	 	 	 
	Dated:	05 FEB 2019	05 FEB 2019	 	Dated:	 
	 	 	 	 	 	 
	ROCHE MOLECULAR SYSTEMS, INC.	 	ENZO LIFE SCIENCES, INC.
	 	 	 	 	 	 
	By:	 	 	 	By:	 
	 	 	 	 	 	 
	[Name] 	 	 	 	[Name] 	 
	[Title]	 	 	 	[Title]	 
	 	 	 	 	 	 
	Dated:		 	 	Dated:	 

 

-10-

    	 

    	

    

f.
Except as expressly provided herein, this Agreement is not intended to confer any benefits or rights upon any Person not a Party
to this Agreement.

 

	ROCHE DIAGNOSTICS GMBH	 	ENZO BIOCHEM, INC.
	 	 	 
	By:	                  	 	By:	                    
	 	 	 	 	 
	[Name]	 	 	[Name]	 
	[Title]	 	 	[Title]	 
	 	 	 	 	 
	Dated:	 	 	Dated:	 
	 	 	 	 	 
	ROCHE MOLECULAR SYSTEMS, INC.	 	ENZO LIFE SCIENCES, INC.
	 	 	 
	By:	/s/ Kevin A. Marks	 	By:	 
	 	 	 	 	 
	[Name] 	Kevin A. Marks	 	[Name]	 
	[Title]	V.P.	 	[Title]	 
	 	 	 	 	 
	Dated:	4 FEB 2019	 	Dated:	 

 

-10-

    	 

    	

    
f.
Except as expressly provided herein, this Agreement is not intended to confer any benefits or rights upon any Person not a Party
to this Agreement.

 

	ROCHE DIAGNOSTICS GMBH	 	ENZO BIOCHEM, INC.
	 	 	                           
	By:	                  	 	By:	/s/ Elazar Rabbani
	 	 	 	 	 
	[Name]	 	 	[Name] 	Elazar Rabbani
	[Title]	 	 	[Title]	CEO
	 	 	 	 	 
	Dated:	 	 	Dated:	Feb 4 2019
	 	 	 	 	 
	ROCHE MOLECULAR SYSTEMS, INC.	 	ENZO LIFE SCIENCES, INC.
	 	 	 
	By:	 	 	By:	/s/ Elazar Rabbani
	 	 	 	 	 
	[Name]	 	 	[Name]	Elazar Rabbani
	[Title]	 	 	[Title]	CEO
	 	 	 	 	 
	Dated:	 	 	Dated:	Feb 4 2019

 

-10-

    	 

    	

    

EXHIBIT A

 

-11-

    	 

    	

    

U.S. Patent Nos.

 

4,707,440
(issued Nov. 17, 1987)

4,711,955 (issued Dec. 8, 1987)

4,943,523 (issued Jul. 24, 1990)

4,994,373 (issued Feb. 19, 1991)

5,013,831 (issued May 7, 1991)

5,082,830 (issued Jan. 21, 1992)

5,175,269 (issued Dec. 29, 1992)

5,241,060 (issued Aug. 31, 1993)

5,328,824 (issued Jul. 12, 1994)

5,449,767 (issued Sep. 12, 1995)

5,476,928 (issued Dec. 19, 1995)

 

-12-

    	 

    	

    

EXHIBIT B

 

-13-

    	 

    	

    

UNITED
STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

 

	 	x	 
	 	 
	 	:	 
	ROCHE DIAGNOSTICS GMBH, and 	:	 
	ROCHE MOLECULAR SYSTEMS, INC.,	:	 
	 	:	04 Civ. 4046 (DLC)
	Declaratory
    Judgment Plaintiffs and 	:	 
	Counterclaim
    Defendants,	:	 
	 	:	 
	- against
    -	:	 
	 	:	 
	ENZO BIOCHEM, INC., and ENZO LIFE 	:	 
	SCIENCES, INC.,	:	 
	 	:	 
	Declaratory
    Judgment Defendants and 	:	 
	Counterclaim
    Plaintiffs.	:	 
	 	:	 
	 	x	 
	 	 

 

STIPULATION OF DISMISSAL

 

IT
IS HEREBY STIPULATED AND AGREED that all claims by Enzo Biochem Inc., and Enzo Life Sciences, Inc. (formerly known as Enzo Diagnostics,
Inc.) against Roche Diagnostics GmbH and Roche Molecular Systems, Inc., in the above-captioned case shall be, and hereby are,
dismissed with prejudice and without fees and costs;

 

IT
IS FURTHER STIPULATED AND AGREED that all claims by Roche Diagnostics GmbH and Roche Molecular Systems, Inc. against Enzo Biochem,
Inc. and Enzo Life Sciences, Inc. (formerly known as Enzo Diagnostics, Inc.) in the above-captioned case shall be, and hereby
are, dismissed with prejudice and without fees and costs;

 

IT
IS FURTHER STIPULATED AND AGREED that this Stipulation is without prejudice to the parties’ rights in any other action;

 

IT
IS FURTHER STIPULATED AND AGREED that this Stipulation may be executed in separate multiple counterparts, each of which shall
be deemed to be an original. Signatures 

 

-14-

    	 

    	

    

provided
through email or facsimile are deemed to be the equivalent of originals for filing purposes.

 

	Dated:	February
    ___, 2019
	 	New York, New
    York
	 	 

	KRAMER
    LEVIN NAFTALIS & FRANKEL LLP	 	WILMER CUTLER PICKERING HALE AND DORR LLP
	 	 	 

	By:	 	 	By:	 
	 	Michael
    J. Dell	 	 	Robert
    J. Gunther, Jr.
	 	Jonathan
    S. Caplan	 	 	Christopher
    R. Noyes
	 	Christine Willgoos	 	 	Omar A. Khan
	 	John P. Dillon	 	 	7 World Trade
    Center
	 	Anna
    Schoenfelder	 	 	250
    Greenwich Street
	 	1177
    Avenue of the Americas	 	 	New
    York, NY 10007
	 	New
    York, NY 10036	 	 	(212)
    230-8800
	 	(212) 715-9100	 	 	 
	 	 	 	 	 

	Attorneys for
    Declaratory Judgment Defendants and Counterclaim
    Plaintiffs Enzo Biochem, Inc. and Enzo Life Sciences,
    Inc.	 	Attorneys for
    Declaratory Judgment Plaintiffs Roche Diagnostics
    GmbH and Roche Molecular Systems, Inc.

 

-15-

    	 

    	

    

EXHIBIT C

 

-16-

    	 

    	

    

	Caption	Court	Docket No.
	Enzo Life Sciences Inc. v. Gen-Probe, Inc.	D. Del.	12-cv-00104
	Enzo Life Sciences Inc. v. Life Technologies Corp.	D. Del.	12-cv-00105
	Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et
    al	D. Del.	12-cv-00106
	Enzo Life Sciences Inc. v. Hologic, Inc.	D. Del.	12-cv-00276
	Enzo Life Sciences Inc. v. Abbott Laboratories, et al	D. Del.	12-cv-00274
	Enzo Life Sciences Inc. v. Becton, Dickinson & Company,
    et al	D. Del.	12-cv-00275
	Enzo Life Sciences Inc. v. Illumina, Inc.	D. Del.	12-cv-00435
	Enzo Life Sciences Inc. v. Adipogen Corp., et al	D. Del.	11-cv-00088
	Enzo Life Sciences Inc. v. Agilent Technologies, Inc.	D. Del.	12-cv-00434
	Enzo Life Sciences Inc. v. Siemens Healthcare Diagnostics, Inc.	D. Del.	12-cv-00505
	Enzo Life Sciences Inc. v. Hologic, Inc.	D. Del.	15-cv-00271
	Enzo Life Sciences Inc. v. Hologic, Inc.	D. Del.	16-cv-00894

 

-17-

    	 

    	

    

EXHIBIT D

 

-18-

    	 

    	

    

UNITED STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
DC 20549

FORM 8-K

 

CURRENT
REPORT PURSUANT TO

SECTION
13 OR 15(D) OF THE

SECURITIES
EXCHANGE ACT OF 1934

 

Date of report
(Date of earliest event reported): February____, 2019

 

Enzo
Biochem, Inc.

(Exact
Name of Registrant as Specified in Its Charter)

 

New
York

(State
or Other Jurisdiction of Incorporation)

 

	001-09974	13-2866202
	(Commission
    File Number)	(IRS
    Employer Identification No.)
	 	 
	527
    Madison Avenue 

New York, New York	10022
	(Address
    of Principal Executive Offices)	(Zip
    Code)

 

(212) 583-0100

(Registrant’s
Telephone Number, Including Area Code)

 

(Former
Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):

 

	o 	Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	 	 
	o	Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	 	 
	o	Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	 	 
	o	Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

-19-

    	 

    	

    

Item 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

 

Enzo Biochem,
Inc. (the “Company”), along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement Agreement as of
February____, 2019 (the “Agreement”) with Roche Diagnostics GmbH and Roche Molecular Systems, Inc. (together, “Roche”)
with respect to an action between the Company and Roche before the U.S. District Court, Southern District of New York, Case No
04-CV-4046. Roche has agreed to pay $21,000,000 in settlement pursuant to the Agreement. This settlement does not affect Enzo’s
civil action for patent infringement against Roche in the U.S. District Court for the State of Delaware, Enzo Life Sciences
Inc. v. Roche Molecular Systems Inc., et al., civil action no. 12-cv-00106, which remains pending on appeal.

 

The
Agreement is filed with this current report as Exhibit 10.1 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

	Exhibit
    No.	Description
	 	 
	10.1	Settlement Agreement as of February_____,
    2019 among Enzo Biochem, Inc., Enzo Life Sciences, Inc., Roche Diagnostics GmbH and Roche Molecular Systems, Inc.

 

-20-

    	 

    	

    

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

 

	 	 	ENZO BIOCHEM, INC.
	 	 	 	 
	Date: February_____,
    2019	 	By: 	/s/ Barry W. Weiner 
	 	 	 	Barry W. Weiner 

President

 

-21-

    	 

    	

    

EXHIBIT
INDEX

 

	10.1	Settlement
    Agreement as of February____, 2019 among Enzo Biochem, Inc., Enzo Life Sciences, Inc.,
    Roche Diagnostics GmbH and Roche Molecular Systems, Inc.

 

-22-

    	 

    	

    

EXHIBIT E

 

-23-

    	 

    	

    

	Biotin-16-UTP
	Biotin-16-dUTP 
	Biotin-16-ddUTP
	Amplichip
    CYP 450
	Microarray RNA Target Synthesis Kit
	Microarray
    cDNA Synthesis Kit
	Microarray
    Target Amplification Kit
	Tetramethylrhodamine-5-dUTP
	Fluorescein-12-dUTP
	Fluorescein-12-UTP
	Amplicor
	COBAS Amplicor
	COBAS
    Amplichip
	Biotin-Chem-Link
	DIG-Chem-Link
	Biotin
    Nick Translation Mix
	Biotin
    High Prime
	Biotin RNA Labeling Mix
	DIG-Nick
    Translation Mix
	DIG
    Oligonucleotide 5’ End Labeling Set
	LightCycler
    2.0 Instrument
	LightCycler
    480 ProbeMaster
	FastStart
    TaqMan ProbeMaster (ROX) High Pure System Viral Nucleic Acid Kit
	Taqman HCV
	Taqman
    HBV
	Taqman
    CV
	Taqman
    NG
	Taqman
    RNA Amplification
	Taqman
    CYP2C9
	Taqman
    Analyzer
	Taqman 48 Analyzer
	Taqman
    98 Analyzer
	COBAS
    201 System
	AmpliPrep Instrument
	COBAS
    AmpliPrep/COBAS Taqman System
	COBAS
    Taqman HCV
	COBAS Taqman HBV
	COBAS
    Ampliprep/COBAS Taqman HIV-1
	COBAS
    Ampliprep/COBAS Taqman HCV
	TaqScreen WNV

 

-24-

    	 

    	

    

	TaqScreen
    MPX
	TaqPrep/COBAS Taqman HBV Monitor Test
	HBV/HCV/NG Oligo Mix/CT/MAI Analyte Specific Reagents
	DIG-11-UTP
	DIG-11-dUTP
	DIG-11-dUTP
    alkali stable
	DIG-11-dUTP alkali labile
	Biotin-11-CTP
	DIG-11-ddUTP
	Universal
    ProbeLibrary
	FastStart TaqMan ProbeMaster
	LightCycler
    TaqMan Master
	Oligo
    (dt)20 Probe
	Biotin-labeled
    Amplicor
	DIG-labeled RNA and DNA molecular weight marker products
	DIG
    Nucleic Acid Detection Kit
	DIG
    Luminescent Detection Kit
	DIG
    DNA Labeling Mix
	Anti-HA-Biotin, High Affinity
	Annexin-V-Biotin
	DIG
    Oligonucleotide 5’-End Labeling Set (11
    480 863 001)
	PCR
    DIG ELISA Kits (11 835297 910)
	DIG-High Prime (11 585 606 910)
	DIG-High
    Prime DNA Labeling Detection Starter Kit II (11 585 614 910)
	PCR
    DIG Probe Synthesis Kit (11 636 090 910)
	PCR
    DIG Labeling Mix Plus (11 835 289 910)
	PCR
    DIG Labeling MIX (11 585 550 910)
	DIG-Nick
    Translation Mix(11745816910)
	DIG
    Oligonucleotide Tailing Kit 2nd generation (03 353583 910)
	DIG
    DNA Labeling Kit (11 175 033 910)
	DIG DNA Labeling and Detection Kit (11 093 657 910)
	DIG-High
    Prime DNA Labeling and Detection Starter Kit I (11 745
    832 910)
	DIG
    RNA Labeling Kit
	DIG
    RNA Labeling Mix
	DIG
    Oligonucleotide 3’ End Labeling Kit, 2nd Generation
	Universal
    ProbeLibrary Set, Human (04 683 633 001)
	Universal
    ProbeLibrary Set, Mouse (04 683 641 001)
	Universal
    ProbeLibrary Set, Rat (04 683 650 001)
	Universal ProbeLibrary Set, Primates (04 683 617 001)
	Universal ProbeLibrary Set, Drosophila (04 683 625 001)
	Universal
    ProbeLibrary Set, C. elegans (04 683 609 001)

 

-25-

    	 

    	

    

	Universal
    ProbeLibrary Set, Arabidopsis (04 683 595 001)
	Universal
    ProbeLibrary Control Set (04 696 417 001)
	Universal
    ProbeLibrary Extension Set, Probes # 91 to # 165 (04 869 877 001)
	Universal
    ProbeLibrary, Zebrafish
	Universal
    ProbeLibrary, Rice
	Universal ProbeLibrary, Maize
	Universal
    ProbeLibrary, Anopheles
	Universal
    ProbeLibrary, Yeast
	Universal ProbeLibrary Set, Human Reference Gene Assays (05 046 114 001)
	Universal
    ProbeLibrary Set, Human ACTB Gene Assay (05 046 165 001)
	Universal
    ProbeLibrary Set, Human BβM Gene Assay (05 189 390 001)
	Universal
    ProbeLibrary Set, Human G6PD Gene Assay (05 046 246 001)
	Universal
    ProbeLibrary Set, Human GAPD Gene Assay (05 190 541 001)
	Universal
    ProbeLibrary Set, Human GUSB Gene Assay (05 190 525 001)
	Universal
    ProbeLibrary Set, Human HPRT Gene Assay (05 046 157 001)
	Universal
    ProbeLibrary Set, Human PBGD Gene Assay (05 046 149 001)
	Universal
    ProbeLibrary Set, Human PGK1 Gene Assay (05 046 173 001)
	Universal
    ProbeLibrary Set, Human PPIA Gene Assay (05 189 268 001)
	Universal
    ProbeLibrary Set, Human TBP Gene Assay (05 189 284 001)
	Universal
    ProbeLibrary Set, Mouse ACTB Gene Assay (05 046 190 001)
	Universal
    ProbeLibrary Set, Mouse GAPD (05 046 211 001)
	Universal
    ProbeLibrary Set, Rat ACTB Gene Assay (05 046 203 001)
	Universal
    ProbeLibrary Set, Rat GAPD Gene Assay (05 046 220 001)
	RealTime
    ready Human Reference Gene Panel, 96 (05 339 545 001)
	RealTime
    ready Human Reference Gene Panel, 384 (05 467 675 001)
	RealTime
    ready Human Apoptosis Panel, 96 (05 392 063 001)
	RealTime
    ready Human Apoptosis Panel, 384 (05 339 316 001)
	RealTime
    ready Human ABC Transporter Panel, 96 (05 339 324 001)
	RealTime
    ready Human ABC Transporter Panel, 384 (05 467 713 001)
	RealTime
    ready Human Cell Cycle, Regulation Panel, 96 (05 339 359 001)
	RealTime
    ready Human Cell Cycle, Regulation Panel, 384 (05 467 683 001)
	RealTime
    ready Human GPCR Panel, 96 (05 353 068 001)
	RealTime
    ready Human GPCR Panel, 384 (05 467 705 001)
	RealTime
    ready Human Nuclear Receptor Panel, 96 (05 339 332 001)
	RealTime
    ready Human Nuclear Receptor Panel, 384 (05 467 691 001)
	RealTime
    ready Custom Panel 96-48+ (05 582 571 001)
	RealTime
    ready Custom Panel 384-48 (05 582 911 001)
	RealTime
    ready Custom Panel 384-48+ (05 582 938 001)
	RealTime
    ready Catalog Assays (05 532 957 001)
	RealTime
    ready Custom Panel 384-384 (05 532 833 001)
	RealTime
    ready Custom panel 384-384+ (05 582 644 001)

 

-26-

    	 

    	

    

	RealTime
    ready Custom Panel 96-16+ (05 582 628 001)
	RealTime
    ready Custom Panel 96-24 (05 532 884 001)
	RealTime
    ready Custom Panel 348-16 (05 583 004 001)
	RealTime
    ready Custom Panel 384-96 (05 582 873 001
	RealTime
    ready Custom Panel 348-32+ (05 582 989 001)
	RealTime
    ready Custom Panel 96-24+ (05 582 610 001)
	RealTime
    ready Custom Panel 348-64+ (05 582 903 001)
	LightCycler®
    480 Control Kits
	Elecsys
    ACTH
	Elecsys
    AFP
	Elecsys
    Anti-HBs
	Elecsys
    anti-TG
	Elecsys
    anti-TPO
	Elecsys
    CA 19-9
	Elecsys
    CA125 II
	Elecsys
    CA15-3 II
	Elecsys
    CEA
	Elecsys
    Cortisol
	Elecsys
    C-Peptide
	Elecsys
    Ferritin
	Elecsys
    Free PSA
	Elecsys
    FSH
	Elecsys
    HCG
	Elecsys
    HCG+β
	Elecsys
    IgE
	Elecsys
    Insulin
	Elecsys
    LH
	Elecsys
    Myoglobin
	Elecsys
    Osteocalcin
	Elecsys
    proBNP
	Elecsys
    Prolactin
	Elecsys
    PSA
	Elecsys PTH (intact)
	Elecsys SHBG
	Elecsys
    Troponin T
	Elecsys
    Troponin-T II
	Elecsys
    TSH
	Elecsys
    β-Crosslaps
	Elecsys
    DHEAS
	Elecsys
    Progesterone II
	Elecsys
    Testosterone

 

-27-

    	 

    	

    

	Elecsys
    Vitamin B12
	Elecsys
    Folate
	Elecsys
    RBC Folate
	Elecsys
    Free T3
	Elecsys
    T3
	Elecsys
    Free T4
	Elecsys T4
	Elecsys
    Estradiol II
	HBsAg
	HBsAg
    Confirmatory
	Elecsys CK-MB
	Cobas
    c 411, 4000, 6000, and 8000 Analyzers
	Elecsys
    2010 Immunoassay Analyzer
	Elecsys
    1010 Immunoassay Analyzer
	Elecsys
    Modular Analytics E170
	HBsAg
    PreciControl
	M1M Analyzer
	Biotin
    Luminsecent Detection Kit
	Luciferase
    Reporter Gene Assay, high sensitivity
	Luciferase
    Reporter Gene Assay, constant light signal
	Cell Proliferation ELISA, BrdU
	Lumi-Light
    PLUS Western Blotting Kit
	BM Chemiluminescence Western Blotting Kit
	Elecsys
    RBC Folate
	Elecsys
    HCG
	Elecsys
    CYFRA 21-1
	Elecsys
    NSE
	Elecsys
    CA 72-4
	Elecsys
    Total PSA
	Elecsys
    TG Calset
	Elecsys
    HIV Ag
	Elecsys
    HIV
	Elecsys
    S 100
	Elecsys
    Digitoxin
	Elecsys
    PTH
	Elecsys
    NT-proBNP
	Elecsys
    Anti-HBc
	Elecsys
    Anti-HBc-IgM
	Elecsys HBeAg
	Elecsys
    Anti-Hbe
	Elecsys Anti-HAV

 

-28-

    	 

    	

    

	Elecsys
    Anti-HAV-IgM
	Elecsys
    TNT II
	Elecsys
    Rubella
	Elecsys
    Toxo
	Elecsys
    Toxo-IgM
	Elecsys
    CA 125
	Elecsys
    CA 15-3
	Elecsys
    T-Uptake
	Elecsys
    total P1NP
	Elecsys
    N-Mid Osteocalcin
	Biotin-DDS
	Biotin Protein Labeling Kit
	Tyrosine Kinase/Phosphatase Substrate I and II
	Biotin-Labeled
    Neuropeptide
	Elecsys
    CK-MB STAT
	Elecsys
    HBsAg Precicontrol
	Elecsys
    Folate II
	Elecsys IgE II
	Elecsys Rubella-IgM
	MAK
    <Myo> M-7005-IgG-Bi (XOSu)
	hyBPRu-DSS-(Bpy)2-Ru-bpy-CO-CO-UEEK-korksaure-Osu
	Flasche
    1 des h-sPLA-2 ELISA (MAK<PLA-2 TypII>4D2 IgG-Bi
	T
    4-DADOO-Ru(bpy)2-bpyCO2H
	PCR ELISA (DIG Detection)
	PCR DIG Labeling Mix
	Biotin
    Chem-Link
	BPRu-Backbone
    2:1
	HBK-Folate
	HBK
	Folate-DADOO-DDS-Bi
	Biotin-MEA
	hyBPPRu_DSS
	hyBPRu-DSS-(Bpy)2-Ru-bpy-CO-CO-UEEK-korksaure-Osu
	BPRu-SK(2)-(UE)25-K
	Soluble
    Transferrin Receptor (sTfR)
	FLASH_HIV
	Biotin-M33-FAB
	Anti-HA-Biotin
    (including High Affinity)
	Northern
    ELISA
	Anti-h-IL-2-Biotin
	TNFR1-Rec-Lig-Assay

 

-29-

    	 

    	

    

	RTS-Biotin Energy Mix MBF
	MAK-IgG1/2a/2b/3-Biotin
    (HAMA ELISA)
	MAK-BiotinM33-FAB(DE)-AP
	IA2-ELISA-TC-Bi-IA2
    F1 1
	Gelatinase
    Activity Assay
	h-IL-4 (ELISA)
	h-IL-12
    ELISA
	Anti-IL-2R-Biotin-Konjugat
	Mykopl
    Detection Kit
	Cellular
    Labeling Kit
	Tumor
    Necrosis Factor-a ELISA
	MAK<Myo>M-7005-Ig-Bi
    (XOSu)
	RTS
    Biotin Feeding Mix
	Diaplets-Anti-IA-2
	Oligo(dT)20, biotin-labeled
	TNFR1
    h (p55) ELISA
	Flasche
    1 des h-sPLA-2 ELISA (MAK<PLA-2 TypII>4D2 IgG-Bi
	h-SICAM-1
    ELISA
	RTS
    AviTag E.coli Biotinylation Kit
	IL-8 huma ELISA TC
	Flashce
    1 des h-Interleukin-16
	ELISA
    (Anti-IL-16-Biotin-Konjugat)
	Tyrosinase
    RT PCR ELISA
	Reverse
    Transciptase Assay
	MAK_HISTON_IgG_Bi
	MAK
    <Histon>M-Hl 1-4-IgG-Bi
	MIA ELISA
	Cell
    Death Detection ELISA
	Mycoplasma PCR ELISA
	Terminal
    Transferase products
	Genius
    Labeling Kits
	DIG
    products
	T7
    Microarray Products
	Reverse Transcriptase Assay
	HIV-2
    primer LTR10BBU
	Genius
    5’ End Labeling Set
	mRNA
    capture kits
	Light
    Cycler products
	CYP
    450 DNA End Labeling Kit
	RNA
    Target Synthesis Kit
	Chem-Link products

 

-30-

    	 

    	

    

	Dig-Omni systems
	Taqman products
	Elecsys
    products
	Microarray target synthesis and amplification kits

 

-31-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]